Inhibition of telomerase limits the growth of human cancer cells

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1164-1170

  Hahn, William C ^a,b,c   Stewart, Sheila A ^a   Brooks, Mary W ^a   York, Shoshana G ^e   Eaton, Elinor ^a   Kurachi, Akiko ^a   Beijersbergen, Roderick L ^a   Knoll, Joan H M ^e,f   Meyerson, Matthew ^b,d   Weinberg, Robert A ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

APOPTOSIS; BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL DIVISION; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; DRUG DESIGN; FEMALE; GENETIC VECTORS; HUMANS; MUTATION; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RETROVIRIDAE; REVERSE TRANSCRIPTASE INHIBITORS; RNA; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

EID: 0032828652     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13495     Document Type: Article

References (57)

1. Hayflick, L. & Moorhead, P.S. The serial cultivation of human diploid cell strains. Exp. Cell. Res. 25, 585-621 (1961).
2. Shay, J.W., Wright, W.E. & Werbin, H. Defining the molecular mechanisms of human cell immortalization. Biochim. Biophys. Acta 1072, 1-7 (1991).
3. Brown, J.P., Wei, W. & Sedivy, J.M. Bypass of senescence after disruption of p21CIPl/WAF1 gene in normal diploid human fibroblasts. Science 277, 831-834 (1997).
4. Sager, R. Senescence as a mode of tumor suppression. Environ. Health Perspect. 93, 59-62 (1991).
5. Barley, C.B. et al. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. 59, 307-315 (1994).
6. Harley, C.B., Futcher, A.B. & Greider, C.W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990).
7. Hastie, N.D. et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346, 866-868 (1990).
8. Blasco, M.A. et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34 (1997).
9. Hande, M.P., Samper, E., Lansdorp, P. & Blasco, M.A. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol. 144, 589-601 (1999).
10. Counter, C.M. et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11, 1921-1929 (1992)
11. Counter, C.M., Hirte, H.W., Bacchetti, S. & Harley, C.B. Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA 91, 2900-2904 (1994).
12. Morales, C.P. et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genet. 21, 115-118 (1999).
13. 3. Greider, C.W. in Telomeres (eds. Blackburn, E.H. & Greider, C.W.) 35-68 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1995).
14. Feng, J. et al. The RNA component of human telomerase. Science 269, 1236-1241 (1995).
15. Nakamura, T.M. et al. Telomerase catalytic subunit homologs from fission yeast and human Science 277, 955-959 (1997).
16. Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795 (1997).
17. 7. Harrington, L. et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11, 3109-3115 (1997).
18. Kilian, A. et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011-2019 (1997).
19. Nakayama, J. et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet. 18, 65-68 (1998).
20. Kim, N.W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994)
21. Ramakrishnan, S., Eppenberger, U., Mueller, H., Shinkai, Y. & Narayanan, R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58, 622-625 (1998).
22. Bodnar, A.G. et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352 (1998).
23. Vaziri, H. & Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279-282 (1998).
24. Counter, C.M. et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. USA 95, 14723-14728 (1998).
25. Halvorsen, T.L., Leibowitz, G. & Levine, F. Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol. Cell. Biol. 19, 1864-1870 (1999).
26. Zhu, J., Wang, H., Bishop, J.M. & Blackburn, E.H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl, Acad. Sci. USA 96, 3723-3728 (1999).
27. Hahn, W.C. et al. Creation of human tumor cells with defined genetic elements. Nature 400; 464-468 (1999).
28. Shay, J.W. & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791 (1997).
29. Nakamura, T.M. & Cech, T.R. Reversing time: origin of telomerase. Cell 92, 587-590 (1998).
30. Counter, C.M., Meyerson, M., Eaton, E.N. & Weinberg, R.A. The catalytic subunit of yeast telomerase. Proc. Natl. Acad. Sci. USA 94, 9202-9207 (1997).
31. Lingner, J. et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276, 561-567 (1997).
32. Weinrich, S.L. et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet. 17, 498-502 (1997).
33. Stewart, N. & Bacchetti, S. Expression of SV40 large T antigen, but not small t antigen, is required for the induction of chromosomal aberrations in transformed human cells. Virology 180, 49-57 (1991).
34. Reddel, R.R., Bryan, T.M. & Murnane, J.P. Immortalized cells with no detectable telomerase activity. A review. Biochemistry (Mosc.) 62, 1254-1262 (1997).
35. Counter, C.M., Botelho, F.M., Wang, P., Harley, C.B. & Bacchetti, S. Stabilization of short telomeres and telomerase activity accompany immortaliza-tion of Epstein-Barr virus-transformed human B lymphocytes. J. Virol. 68, 3410-3414 (1994).
36. Rufer, N., Dragowska, W., Thornbury, G., Roosnek, E. & Lansdorp, P.M. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nature Biotechnol. 16, 743-747 (1998).
37. Goi, K. et al. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 57, 1895-1902 (1997).
38. Karlseder, J., Broccoli, D., Dai, Y., Hardy, S. & de Lange, T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283, 1321-1325 (1999).
39. Strobel, T., Tai, Y.-T., Korsmeyer, S. & Cannistra, S.A. BAD partly reverses paclitaxel resistance in human ovarian carcinoma cells. Oncogens 17, 2419-2427 (1998).
40. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and CADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
41. Glukhov, A.I., Zimnik, O.V., Gordeev, S.A. & Severin, S.E. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonudeotides. Biochem. Biophys. Res. Commun. 248, 368-371 (1998).
42. Bisoffi, M. et al. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA. Eur. J. Cancer 34, 1242-1249 (1998).
43. Kondo, S. et al. Antisense telomerase treatment: induction ol two distinct pathways, apoptosisand differentiation. FASEB J. 12, 801-811 (1998).
44. Norton, J.C, Piatyszek, M.A., Wright, W.E., Shay, J.W. & Corey, D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnol. 14, 615-619 (1996).
45. Lundblad, V. & Blackburn, E.H. An alternative pathway for yeast telomere maintenance rescues est1-senescence. Cell 73, 347-360 (1993).
46. Nakamura, T.M., Cooper, J.P. & Cech, T.R. Two modes of survival of fission yeast without telomerase. Science 282, 493-496 (1998).
47. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
48. Aas, T. et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2, 811-814 (1996).
49. Lowe, S.W., Ruley, H.E., lacks, T. & Houseman, S.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-968 (1993).
50. Chin, L. et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527-538 (1999).
51. de Lange, T. et al. Structure and variability of human chromosome ends. Mol. Cell. biol. 10, 518-527 (1990).
52. Strahl, C. & Blackburn, E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16, 53-65 (1996).
53. Morgenstern, J.P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596 (1990).
54. Kim, N.W. & Wu, F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25, 2595-2597 (1997).
55. Seabright, M. A rapid banding technique for human chromosomes. Lancet 2, 971-972 (1971).
56. Landsdorp, P.M. et al. Heterogeneity in telomere length of human chromosomes. Hum. Mol. Genet. 5, 685-691 (1996).
57. Schmid, I., Uittenbogaart, C.H. & Giorgi, J.V. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 12, 279-285 (1991).